Cellectar Biosciences Company Profile (NASDAQ:CLRB)

About Cellectar Biosciences (NASDAQ:CLRB)

Cellectar Biosciences logoCellectar Biosciences, Inc., formerly Novelos Therapeutics, Inc., is a clinical stage biopharmaceutical company. The Company is engaged in developing phospholipid ether-drug conjugates (PDCs) for the treatment and diagnostic imaging of cancer. Its research and development program is based on its PDC cancer targeting delivery platform. Its pipeline consists of pre-clinical and clinical product candidates, including radiotherapeutic and chemotherapeutic PDC's. The Company's PDC product portfolio includes CLR 131, which is designed to deliver cytotoxic (cell-killing) radiation directly and selectively to cancer cells and cancer stem cells; CLR 125, which is for the treatment of micro metastatic disease; CLR 124, which is a cancer-targeting positron emission tomography (PET) imaging PDC; CLR 1502, which is for intraoperative tumor margin illumination and non-invasive tumor imaging, and CTX Product Portfolio, including CLR 1601-PTX, CLR 1602-PTX and CLR 1603-PTX product candidates.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Pharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CLRB
  • CUSIP: N/A
  • Web: www.cellectar.com
Capitalization:
  • Market Cap: $24.78 million
  • Outstanding Shares: 13,922,000
Average Prices:
  • 50 Day Moving Avg: $1.63
  • 200 Day Moving Avg: $1.82
  • 52 Week Range: $1.12 - $3.19
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.87
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $0.81 per share
  • Price / Book: 2.12
Profitability:
  • EBIDTA: ($10,780,000.00)
  • Return on Equity: -97.36%
  • Return on Assets: -83.40%
Debt:
  • Current Ratio: 5.91%
  • Quick Ratio: 5.91%
Misc:
  • Average Volume: 231,792 shs.
  • Beta: 1.05
  • Short Ratio: 13.63
 

Frequently Asked Questions for Cellectar Biosciences (NASDAQ:CLRB)

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) issued its earnings results on Monday, August, 14th. The company reported ($0.23) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.01. View Cellectar Biosciences' Earnings History.

When will Cellectar Biosciences make its next earnings announcement?

Cellectar Biosciences is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Cellectar Biosciences.

Where is Cellectar Biosciences' stock going? Where will Cellectar Biosciences' stock price be in 2017?

2 brokerages have issued twelve-month price objectives for Cellectar Biosciences' shares. Their forecasts range from $2.70 to $2.70. On average, they anticipate Cellectar Biosciences' stock price to reach $2.70 in the next year. View Analyst Ratings for Cellectar Biosciences.

Who are some of Cellectar Biosciences' key competitors?

Who are Cellectar Biosciences' key executives?

Cellectar Biosciences' management team includes the folowing people:

  • Stephen Anthony Hill M.D., Chairman of the Board
  • James V. Caruso, President, Chief Executive Officer, Director
  • Chad J. Kolean, Chief Financial Officer, Vice President - Finance, Treasurer
  • Jarrod Longcor, Senior Vice President - Corporate Development and Operations
  • Cameron Szakacs Ph.D., Vice President - Clinical Development
  • Frederick W. Driscoll, Director
  • Douglas J. Swirsky, Director
  • Stefan D. Loren Ph.D., Independent Director
  • John P. Neis, Independent Director

Who owns Cellectar Biosciences stock?

Cellectar Biosciences' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (1.09%) and Virtu KCG Holdings LLC (0.48%). Company insiders that own Cellectar Biosciences stock include Awm Investment Company, Inc, James V Caruso, John Neis, Paul L Berns and Richard Hertzberg. View Institutional Ownership Trends for Cellectar Biosciences.

Who bought Cellectar Biosciences stock? Who is buying Cellectar Biosciences stock?

Cellectar Biosciences' stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Virtu KCG Holdings LLC. Company insiders that have bought Cellectar Biosciences stock in the last two years include James V Caruso, John Neis and Paul L Berns. View Insider Buying and Selling for Cellectar Biosciences.

How do I buy Cellectar Biosciences stock?

Shares of Cellectar Biosciences can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Cellectar Biosciences' stock price today?

One share of Cellectar Biosciences stock can currently be purchased for approximately $1.72.


MarketBeat Community Rating for Cellectar Biosciences (NASDAQ CLRB)
Community Ranking:  2.6 out of 5 (star star)
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  31 (Vote Underperform)
Total Votes:  64
MarketBeat's community ratings are surveys of what our community members think about Cellectar Biosciences and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Cellectar Biosciences (NASDAQ:CLRB) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.70 (56.98% upside)

Analysts' Ratings History for Cellectar Biosciences (NASDAQ:CLRB)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
12/21/2016Ladenburg Thalmann Financial ServicesInitiated CoverageBuy$2.70N/AView Rating Details
12/21/2016Langenberg & CompanyInitiated CoverageBuy$2.70N/AView Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Cellectar Biosciences (NASDAQ:CLRB)
Earnings by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
Earnings History by Quarter for Cellectar Biosciences (NASDAQ CLRB)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017($0.25)N/AView Earnings Details
8/14/2017Q2 2017($0.24)($0.23)ViewN/AView Earnings Details
5/11/2017Q1 2017($0.23)($0.24)ViewN/AView Earnings Details
3/15/2017Q4 2016($0.23)($0.35)ViewN/AView Earnings Details
11/10/2016Q3 2016($0.20)($0.43)ViewN/AView Earnings Details
8/11/2016Q2 2016($0.40)($0.49)ViewN/AView Earnings Details
11/12/2015Q315($0.25)ViewListenView Earnings Details
8/12/2015Q215($0.30)ViewListenView Earnings Details
5/21/2015Q115($0.30)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Cellectar Biosciences (NASDAQ:CLRB)
Current Year EPS Consensus Estimate: $-0.92 EPS
Next Year EPS Consensus Estimate: $-0.92 EPS

Dividends

Dividend History for Cellectar Biosciences (NASDAQ:CLRB)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Cellectar Biosciences (NASDAQ:CLRB)
Insider Ownership Percentage: 10.17%
Institutional Ownership Percentage: 2.63%
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
Insider Trades by Quarter for Cellectar Biosciences (NASDAQ:CLRB)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/29/2016John NeisDirectorBuy333,333$1.49$496,666.17View SEC Filing  
10/31/2016Richard HertzbergInsiderSell21,000$2.03$42,630.00View SEC Filing  
4/20/2016James V CarusoCEOBuy46,948$2.12$99,529.76View SEC Filing  
4/20/2016Paul L BernsDirectorBuy117,371$2.12$248,826.52View SEC Filing  
12/31/2015Awm Investment Company, Inc.Major ShareholderSell100,000$0.69$69,000.00View SEC Filing  
12/29/2015Awm Investment Company, Inc.Major ShareholderSell82,847$0.69$57,164.43View SEC Filing  
12/28/2015Awm Investment Company, Inc.Major ShareholderSell367,966$0.73$268,615.18View SEC Filing  
12/22/2015Awm Investment Company, Inc.Major ShareholderSell7,938$0.90$7,144.20View SEC Filing  
12/21/2015Awm Investment Company, Inc.Major ShareholderSell27,621$0.92$25,411.32View SEC Filing  
12/17/2015Awm Investment Company, Inc.Major ShareholderSell71,225$0.87$61,965.75View SEC Filing  
12/15/2015Awm Investment Company, Inc.Major ShareholderSell44,965$0.82$36,871.30View SEC Filing  
12/4/2015Awm Investment Company, Inc.Major ShareholderSell50,950$1.06$54,007.00View SEC Filing  
11/24/2015Awm Investment Company, Inc.Major ShareholderSell173,802$1.24$215,514.48View SEC Filing  
11/24/2015James V CarusoCEOBuy1,000$1.30$1,300.00View SEC Filing  
11/20/2015Awm Investment Company, Inc.Major ShareholderSell96,806$1.17$113,263.02View SEC Filing  
11/20/2015James V CarusoCEOBuy1,000$1.16$1,160.00View SEC Filing  
11/19/2015James V. CarusoCEOBuy4,000$1.45$5,800.00View SEC Filing  
10/23/2015Awm Investment Company, Inc.Major ShareholderSell8,866$2.00$17,732.00View SEC Filing  
10/6/2015Awm Investment Company, Inc.Major ShareholderSell2,554$2.00$5,108.00View SEC Filing  
10/5/2015Awm Investment Company, Inc.Major ShareholderSell7,500$2.04$15,300.00View SEC Filing  
10/1/2015Awm Investment Company, Inc.Major ShareholderSell27,940$2.05$57,277.00View SEC Filing  
9/29/2015Awm Investment Company, Inc.Major ShareholderSell24,801$2.36$58,530.36View SEC Filing  
8/20/2014John NeisDirectorBuy268,711$3.75$1,007,666.25View SEC Filing  
8/20/2014Simon PedderCEOBuy13,300$3.75$49,875.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Cellectar Biosciences (NASDAQ:CLRB)
Latest Headlines for Cellectar Biosciences (NASDAQ:CLRB)
Source:
DateHeadline
finance.yahoo.com logoCellectar Biosciences Enters into Strategic Collaboration with Onconova Therapeutics to Develop New Phospholipid Drug Conjugates
finance.yahoo.com - September 21 at 10:30 AM
globenewswire.com logoCellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference - GlobeNewswire (press release)
globenewswire.com - September 20 at 11:05 PM
finance.yahoo.com logoCellectar Biosciences to Present at the Ladenburg Thalmann 2017 Healthcare Conference
finance.yahoo.com - September 20 at 6:04 PM
globenewswire.com logoCellectar Biosciences Appoints Jarrod Longcor Chief Business Officer - GlobeNewswire (press release)
globenewswire.com - September 18 at 8:46 PM
finance.yahoo.com logoCellectar Biosciences Appoints Jarrod Longcor Chief Business Officer
finance.yahoo.com - September 18 at 3:44 PM
americanbankingnews.com logoTheravance Biopharma (TBPH) versus Cellectar Biosciences (CLRB) Head-To-Head Survey
www.americanbankingnews.com - September 17 at 4:46 PM
seekingalpha.com logoCellectar Biosciences (CLRB) Presents At Rodman & Renshaw 19th Annual Global Investment Conference - Slideshow
seekingalpha.com - September 13 at 11:37 PM
americanbankingnews.com logoCellectar Biosciences, Inc. (CLRB) Raised to Hold at Zacks Investment Research
www.americanbankingnews.com - September 8 at 9:18 PM
globenewswire.com logoCellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference - GlobeNewswire (press release)
globenewswire.com - September 6 at 10:23 PM
finance.yahoo.com logoCellectar Biosciences to Present at the 19th Annual Rodman and Renshaw Global Investment Conference
finance.yahoo.com - September 6 at 5:16 PM
americanbankingnews.com logoCellectar Biosciences, Inc. (CLRB) Upgraded at ValuEngine
www.americanbankingnews.com - September 3 at 6:32 PM
americanbankingnews.com logoCellectar Biosciences, Inc. (CLRB) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - August 25 at 8:28 PM
baystreet.ca logoPipeline News Pushes Cellectar to Again Test 200 Day Moving Average
www.baystreet.ca - August 22 at 5:51 PM
globenewswire.com logoCellectar Biosciences Announces Significant PDC Platform Advancement; Demonstrates Potential to Improve Therapeutic Window
globenewswire.com - August 22 at 5:51 PM
americanbankingnews.com logoCellectar Biosciences, Inc. (CLRB) Downgraded by Zacks Investment Research
www.americanbankingnews.com - August 18 at 8:20 PM
finance.yahoo.com logoEdited Transcript of CLRB earnings conference call or presentation 14-Aug-17 9:00pm GMT
finance.yahoo.com - August 15 at 5:59 PM
americanbankingnews.com logoCellectar Biosciences, Inc. (CLRB) Releases Quarterly Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - August 15 at 2:22 PM
globenewswire.com logoCellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance - GlobeNewswire (press release)
globenewswire.com - August 14 at 5:42 PM
finance.yahoo.com logoCellectar Biosciences Reports Second Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - August 14 at 5:42 PM
streetinsider.com logoCellectar Biosciences (CLRB) Says CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
www.streetinsider.com - August 10 at 6:33 PM
streetinsider.com logoCellectar Biosciences (CLRB) Says CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced ... - StreetInsider.com
www.streetinsider.com - August 9 at 3:00 AM
finance.yahoo.com logoCellectar Biosciences’ CLR 131 Achieves Overall Survival of Greater Than 22 Months in Advanced Multiple Myeloma Patients
finance.yahoo.com - August 8 at 4:59 PM
nasdaq.com logoCellectar Biosciences to Host Conference Call on August 14, 2017 ... - Nasdaq
www.nasdaq.com - August 4 at 4:57 AM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call on August 14, 2017 to Report Second Quarter 2017 Financial Results and Corporate Performance
finance.yahoo.com - August 3 at 6:51 PM
streetinsider.com logoCellectar Biosciences (CLRB) Enters Pact with Avicenna Oncology to Develop New PDCs for Solid Tumors
www.streetinsider.com - August 2 at 6:03 PM
americanbankingnews.com logoCellectar Biosciences, Inc. (NASDAQ:CLRB) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - August 2 at 7:20 AM
streetinsider.com logoCellectar Biosciences (CLRB) Enters Pact with Avicenna Oncology ... - StreetInsider.com
www.streetinsider.com - August 1 at 5:58 PM
finance.yahoo.com logoCellectar Biosciences Signs Collaboration with Avicenna Oncology to Develop New PDCs for Solid Tumors
finance.yahoo.com - August 1 at 5:58 PM
prnewswire.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential ... - PR Newswire (press release)
www.prnewswire.com - June 15 at 11:12 PM
finance.yahoo.com logoSHAREHOLDER ALERT: Purcell Julie & Lefkowitz LLP Is Investigating Cellectar Biosciences, Inc. for Potential Breaches Of Fiduciary Duty By Its Board of Directors
finance.yahoo.com - June 15 at 6:10 PM
globenewswire.com logoCellectar Biosciences to Present at the 2017 Marcum MicroCap Conference - GlobeNewswire (press release)
globenewswire.com - June 7 at 2:37 PM
finance.yahoo.com logoCellectar Biosciences to Present at the 2017 Marcum MicroCap Conference
finance.yahoo.com - June 6 at 4:33 PM
globenewswire.com logoCellectar Biosciences to Present at the LD Micro Invitational Conference - GlobeNewswire (press release)
globenewswire.com - June 1 at 2:27 AM
finance.yahoo.com logoCellectar Biosciences to Present at the LD Micro Invitational Conference
finance.yahoo.com - May 30 at 12:02 PM
americanbankingnews.com logoCellectar Biosciences Inc (CLRB) Stock Rating Lowered by ValuEngine
www.americanbankingnews.com - May 23 at 5:04 PM
globenewswire.com logoThree Abstracts on Dosing Regimens of Cellectar's CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 4:16 PM
finance.yahoo.com logoThree Abstracts on Dosing Regimens of Cellectar’s CLR 131 in a Variety of Tumor Types Published in the 2017 ASCO Annual Meeting Proceedings
finance.yahoo.com - May 18 at 11:10 AM
reuters.com logoBRIEF-Cellectar Biosciences Q1 loss per share $0.24
www.reuters.com - May 12 at 9:56 PM
finance.yahoo.com logoEdited Transcript of CLRB earnings conference call or presentation 11-May-17 8:30pm GMT
finance.yahoo.com - May 12 at 4:53 PM
americanbankingnews.com logoCellectar Biosciences Inc (CLRB) Issues Quarterly Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - May 12 at 2:02 PM
finance.yahoo.com logoCellectar Biosciences Reports First Quarter 2017 Financial and Corporate Performance
finance.yahoo.com - May 11 at 4:58 PM
prnewswire.com logoBiotech Stocks on Investors' Radar -- BioMarin Pharma, Eyegate Pharma, Navidea Biopharma, and Cellectar Biosciences - PR Newswire (press release)
www.prnewswire.com - May 9 at 8:12 AM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and ... - Yahoo Finance
finance.yahoo.com - May 4 at 8:24 AM
americanbankingnews.com logoCellectar Biosciences (CLRB) Receives Media Sentiment Rating of 0.46
www.americanbankingnews.com - May 3 at 4:18 PM
finance.yahoo.com logoCellectar Biosciences to Host Conference Call on May 11, 2017 to Report First Quarter 2017 Financial Results and Corporate Performance
finance.yahoo.com - May 2 at 4:22 PM
americanbankingnews.com logoCellectar Biosciences (CLRB) Getting Somewhat Favorable Press Coverage, Report Shows
www.americanbankingnews.com - April 28 at 11:38 PM
finance.yahoo.com logoCellectar's Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical ... - Yahoo Finance
finance.yahoo.com - April 27 at 9:53 PM
streetinsider.com logoCellectar Biosciences (CLRB) Says CLR 131 and CLR 125 Demonstrate Increased Survival Benefit Using Multiple Doses in Preclinical Studies
www.streetinsider.com - April 27 at 9:56 AM
finance.yahoo.com logoCellectar’s Radiotherapeutic PDCs Demonstrate an Increased Survival Benefit Using Multiple Doses in Preclinical Studies
finance.yahoo.com - April 27 at 9:56 AM
streetinsider.com logoCellectar Biosciences (CLRB) Announces Patents for PDC Optical Agents in Detection of Multiple Cancers
www.streetinsider.com - April 25 at 12:11 PM

Social

Chart

Cellectar Biosciences (CLRB) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff